GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PhoenixBio Co 6190.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

236

-3.28%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About PhoenixBio Co

Its shares trade on Tokyo Stock Exchange under the ticker 6190.T. It has been listed since 18 March 2016. In the fiscal year to 31 March 2026, it reported revenue of ¥1.57bn and net income of ¥125.2m. At that date it held total assets of ¥2.19bn and shareholders' equity of ¥1.55bn.

PhoenixBio Co., Ltd. operates as a holding company that develops technologies for mass propagation of human cells into laboratory animals. The company is headquartered in Higashihiroshima-Shi, Hiroshima-Ken. The company went IPO on 2016-03-18. The PXB Mouse segment is engaged in the development of technology to create PXB Mouse in which more than 70% of mouse livers are replaced with human hepatocytes. The product called PXB Mouse is used in the preclinical process of the discovery of drugs.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
18 Mar 2016
Employees
65

Leadership

Pay as last reported

  • Mr. Takashi ShimadaPresident, Chief Executive Officer, Chairman of Subsidiaries, Representative Director, since 2002
  • Mr. Yasuhiro TamuraSenior Managing Director, Director of Administration, since 2005
  • Ms. Chise MukaidaniDirector of Research & Development, Director of Production, Director, since 2007
  • Mr. Yoshinori FujiiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PXB Mouse segment develops technology for human hepatocytes in mouse livers over 70%.
  • PhoenixBio employs 65 full-time employees in Higashihiroshima-shi, Japan.
  • PhoenixBio's PXB Mouse is used in preclinical drug discovery processes.

Weaknesses

  • PhoenixBio has only 65 employees, limiting scalability in Health Care sector.
  • PXB Mouse segment focuses on a single product, PXB Mouse, with limited diversification.
  • PhoenixBio's operations are confined to Higashihiroshima-shi, Japan, restricting global reach.

Opportunities

  • PXB Mouse technology can expand into global pharmaceutical markets for drug discovery.
  • Health Care sector growth in Japan offers potential for PhoenixBio's PXB Mouse segment.
  • Life Sciences Tools & Services industry expansion provides new market opportunities.

Threats

  • Competition in Life Sciences Tools & Services could challenge PhoenixBio's PXB Mouse segment.
  • Regulatory changes in Health Care might affect PXB Mouse development and use.
  • Economic downturns in Japan could reduce investment in pharmaceutical research.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.